ASCO 2018 | Pazopanib for progressive desmoid tumors

Maud Toulmonde

There have previously been no randomized trials assessing systemic therapy activity for progressive desmoid tumors. Here, Maud Toulmonde, MD, of the Institut BergoniƩ, Bordeaux, France, discusses the aims, methods and results of the DESMOPAZ trial (NCT01876082). This French Sarcoma Group trial investigated the use of pazopanib vs. IV methotrexate/vinblastine in desmoid tumors. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video